Financial Performance Highlights - Revenue reached RMB 41,067 million, a year-on-year decrease of 080%[5] - R&D expense was RMB 3,644 million, a year-on-year decrease of 1615%[6] - Net profit attributable to shareholders was RMB 2,770 million, a year-on-year increase of 1608%[7] - Net operating cash flow reached RMB 4,470 million, a year-on-year increase of 3113%[6] Key Products and R&D - Serplulimab Injection (PD-1) achieved revenue of RMB 1,313 million in 2024[68, 130] - Pharma R&D expenditure was RMB 4,910 million, accounting for 1698% of Pharma revenue[63, 67] - Axicabtagene Ciloleucel Injection has benefited over 800 patients since approval in 2021[43, 75, 132] Global Operations and Internationalization - Revenue from countries and regions outside Chinese mainland reached RMB 11,297 million, a year-on-year increase of 893%[30] - Sisram's direct sales revenue increased to 87%[36, 100] Medical Devices - Sisram Medical's revenue was USD 3590 million in 2024[99] - 58 Da Vinci Surgical Systems were installed in China in 2024[108] Sinopharm Performance - Pharmaceutical distribution segment revenue recorded RMB 444,365 million, a year-on-year increase of 075%[121] - Medical device distribution segment revenue recorded RMB 117,915 million, a year-on-year decrease of 944%[121] - Retail pharmacy segment revenue recorded RMB 35,981 million, a year-on-year increase of 082%[121]
复星医药(02196) - 2024 H2 - 电话会议演示